Apelin-potential therapy for COVID-19?
Authors:
- 1 August 2020
- journal article
- research article
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 145, 84-87
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Interactive effects of apelin, renin–angiotensin system and nitric oxide in treatment of obesity-induced type 2 diabetes mellitus in male albino ratsArchives of Physiology and Biochemistry, 2018
- Recombinant human ACE2: acing out angiotensin II in ARDS therapyCritical Care, 2017
- Cardiac action of the first G protein biased small molecule apelin agonistBiochemical Pharmacology, 2016
- Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular systemTrends in Pharmacological Sciences, 2015
- Design, Characterization, and First-In-Human Study of the Vascular Actions of a Novel Biased Apelin Receptor AgonistHypertension, 2015
- Apelin is a positive regulator of ACE2 in failing heartsJournal of Clinical Investigation, 2013
- Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 productionJournal Of Hypertension, 2011
- Acute Cardiovascular Effects of Apelin in HumansCirculation, 2010
- The Prothrombotic Paradox of HypertensionHypertension, 2005
- A Human Homolog of Angiotensin-converting EnzymeJournal of Biological Chemistry, 2000